Acrivon Therapeutics (NASDAQ:ACRV) Earns Market Outperform Rating from Citizens Jmp

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by analysts at Citizens Jmp in a research note issued to investors on Tuesday, Benzinga reports.

A number of other research firms also recently commented on ACRV. Jefferies Financial Group reiterated a “buy” rating on shares of Acrivon Therapeutics in a research report on Wednesday, November 11th. Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Finally, Weiss Ratings raised Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $13.50.

View Our Latest Stock Analysis on ACRV

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV opened at $1.56 on Tuesday. The firm has a market capitalization of $66.94 million, a price-to-earnings ratio of -0.85 and a beta of 1.96. The business’s 50 day simple moving average is $1.79 and its 200-day simple moving average is $1.74. Acrivon Therapeutics has a 12 month low of $1.27 and a 12 month high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. On average, equities analysts anticipate that Acrivon Therapeutics will post -1.71 earnings per share for the current year.

Insider Activity at Acrivon Therapeutics

In other news, CEO Peter Blume-Jensen sold 14,036 shares of Acrivon Therapeutics stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total transaction of $31,019.56. Following the completion of the sale, the chief executive officer directly owned 2,230,052 shares in the company, valued at $4,928,414.92. The trade was a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 14,843 shares of company stock worth $32,549 in the last ninety days. Insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. StoneX Group Inc. acquired a new stake in Acrivon Therapeutics during the third quarter worth approximately $43,000. Spark Investment Management LLC purchased a new stake in Acrivon Therapeutics in the 2nd quarter worth approximately $50,000. Empowered Funds LLC acquired a new position in Acrivon Therapeutics in the 3rd quarter valued at $117,000. Marshall Wace LLP raised its holdings in Acrivon Therapeutics by 2.0% in the 3rd quarter. Marshall Wace LLP now owns 542,344 shares of the company’s stock valued at $1,112,000 after acquiring an additional 10,488 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Acrivon Therapeutics by 19.6% in the 1st quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock valued at $1,054,000 after acquiring an additional 124,271 shares during the last quarter. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

See Also

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.